**H2-O deficiency promotes regulatory T cell differentiation and CD4 T cell hyperactivity**

Robin A. Welsh[1], Nianbin Song[1], Chan-su Park[1,2], J. David Peske[1], Scheherazade Sadegh-
Nasseri[1,4*]

[1]Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
[2]Current Address: Department of Pharmaceutics, College of Pharmacy, Chungbuk National
University, 1 Chungdae-ro, Seowon-gu, Cheongju 28644, Korea
[4]Senior Author
*Corresponding Author: ssadegh@jhmi.edu

**Abstract**

Regulatory T cells (Treg) are crucial immune modulators, yet the exact mechanism of thymic

Treg development remains controversial. Here, we present the first direct evidence for H2-O,

an MHC class II peptide editing molecular chaperon, on selection of thymic Tregs. We provide

evidence that lack of H2-O in the thymic medulla promotes thymic Treg development and leads

to an increased peripheral Treg frequency. Single-cell RNA-sequencing (scRNA-seq) analysis of

splenic CD4 T cells revealed not only of an enrichment of effector-like Tregs but also of

activated CD4 T cells in the absence of H2-O. Our data support two concepts; a) lack of H2-O

expression in the thymic medulla creates an environment permissive to Treg development and,

b) that loss of H2-O drives increased basal auto-stimulation of CD4 T cells. These findings can

help in better understanding of predispositions to autoimmunity and design of therapeutics for

treatment of autoimmune diseases.

# Introduction

T cells are key players in humoral immune responses. Upon infection with a pathogen,

CD4 T cells utilize their T cell receptor (TCR) to survey peptides presented by professional

antigen presenting cells (APCs) on class II molecules (pMHCII) for recognition. Identification of a

cognate pMHCII complex by the TCR leads to CD4 T cell activation and ultimately clearance of

the foreign pathogen. Faulty activation, however, can lead to deleterious inflammation causing

possible autoimmune diseases and cancer development. Therefore, multiple regulatory

processes exist to ensure proper T cell activation.

Regulation of T cell activation begins during thymic development where immature

thymocytes are screened for self-reactivity. Broadly divided into positive and negative

selection, this process ensures that CD4 T cells expressing high avidity self-reactive TCRs are

either eliminated (1), or become CD4 regulatory T cells (Tregs) (2). Critical to the screening

process for identifying auto-reactive T cells is the Class II antigen processing machinery

expressed by medullary thymic epithelium cells (mTECs) and thymic antigen presenting cells

(APCs). Two chaperone proteins, H2-M (murine; human, HLA-DM), and H2-O (murine; human,

HLA-DO) are major components of the MHC II processing pathway. While H2-M is expressed in

all APCs, H2-O was originally discovered to be expressed in the thymic medulla and B cells (3). It

was only later that HLA-DO was reported to be expressed on cross presenting CD8$\alpha\alpha$+ DC (4),

then followed by identification of H2-O on murine CD8$\alpha\alpha$+ DC (5). H2-M plays a critical role in

MHC class II antigen processing by dissociating the Class II Invariant Chain peptide (CLIP) from

the newly synthesized MHC II. Dissociation of CLIP promotes a peptide-receptive MHC II

conformation that can readily scan denatured antigens for the best MHC II groove fitting

epitopes. However, a peptide-receptive MHC II conformation is highly transient (6, 7, 8, 9). We

have proposed that H2-O binds to H2-M (10) and works cooperatively with H2-M by stabilizing

the peptide-receptive MHC II conformation in order to optimize epitope selection (11).

Together, these two molecules can ensure that the best MHC II groove fitting epitopes are

presented to cognate CD4 T cells.

While the exact mechanism of Treg selection remains to be fully understood (12), two

critical requirements have been identified as necessary for successful thymic Treg development.

First, thymic Treg development requires relatively strong TCR signaling in the thymic medulla

(13), and second, Treg development relies on signaling by common γ chain (γC) cytokines,

mainly IL-2, for driving Foxp3 expression (14). Considering that strong TCR signaling during

negative selection normally leads to CD4 T cell deletion (1), when investigating Treg selection,

both the nature and density of medulla presented self-peptides must be considered. If epitopes

are in high abundance and more ubiquitously expressed, then cognate CD4 T cells will undergo

clonal deletion. However, if epitopes are in lower abundance and have a sparser expression,

leading to discontinuous TCR stimulation, then cognate CD4 T cells might undergo Treg

selection (12, 15, 16). This model of Treg selection relies on the level of TCR signaling that

medulla localized CD4 single-positive (SP) T cells receive. Should a lower density of self pMHCII

be presented in the thymic medulla to CD4 T cells undergoing negative selection, an increased

number of self-reactive CD4 T cells might escape deletion, leading to an increased frequency of

auto-reactive T cell clones in the periphery. Alternatively, presentation of a lower density of self

pMHCII could promote selection of regulatory T cells. Here, we demonstrate that loss of H2-O

generates a more stimulatory *in vivo* environment impacting both the thymic development and

peripheral activation of regulatory T cells.

77                                         **Results**

**Loss of H2-O increases the activation state of auditing medulla CD4 T cells**

Previously, we demonstrated that loss of H2-O expression correlated with both an

increased B cell presentation of low-affinity MHC II peptides, and an increased frequency of a

$MOG_{35-55}$ specific, self-reactive CD4 T cell (17). Because of H2-O expression in the medullary

thymus we speculated that H2-O deficiency might lead to presentation of lower densities of

high-affinity self-peptides in the medulla, thereby causing altered clonal deletion. Positively

selected (TCR-$\beta$+ CD5+) medulla CD4 T cells (**Fig 1a/sFig1**) from the thymi of 6 week old male

and female H2-O WT and H2-O mice were subdivided into "Auditing" (CCR7+ CD4+ Caspase-

$3_{neg}$) and "Clonally Deleted" (CCR7+ CD4+ Caspase-$3_{pos}$) CD4 T cells for evaluation of negative

selection.

Loss of H2-O was found to significantly increase the expression of the activation marker

CD69 on CD4 T cells undergoing active self-auditing, but not those selected for clonal deletion

(**Fig 1a**). CD69 in combination with MHC-I defines 3 medullary maturation stages: semi-mature

(CD69+ MHC-I -), mature 1 (CD69+ MHC-I +), and mature 2 (CD69- MHC-I -) (18). Subdivision of

auditing H2-O-KO CD4 T cells identified a significant increase in CD4 T cells with a Mature 1

phenotype (**Fig 1b, sFig2**). Conversely, both the semi-mature and mature 2 stages were

decreased in H2-O KO mice (**Fig 1b left/right**). No differences in any maturation stage were

found in the clonally deleted CD4 T cell populations (**sFig2). Furthermore,** H2-O deficiency, did

not appear to alter the rate of CD4 T cells undergoing clonal deletion (**Fig 1c**). Importantly, no

differences were observed in thymocytes undergoing positive selection (**sFig 3**). These data

suggest that loss of H2-O drives a more stimulatory thymic medulla environment, but with

similar levels of clonal deletion. It is therefore likely that the increased peripheral frequencies of

MOG-specific CD4 T cells previously identified is due to increased peripheral expansion of the

MOG-reactive clone, not a general alteration in clonal deletion.

**H2-O KO thymi have increased frequencies of regulatory T cells**

With increased levels of peripheral Tregs previously identified in H2-O KO mice (17), we

also questioned if H2-O deficiency was affecting Treg selection. In fact, one model of thymic

Treg selection centers around the concept of antigen density (15, 19). Within this "mosaic"

model, sporadic MHC-TCR interactions with sparsely presented self-epitopes leads to Treg

development. Since it has been shown that peripheral loss of H2-O leads to alterations in

peptide presentation (17, 20, 21), we postulated that altering the level of self-epitopes present

in the medulla could alter Treg selection.

Analysis of CD4 single-positive T cells identified an increased frequency of CD25+Foxp3+

T cells in H2-O KO mice (**Fig 2a**). Furthermore, H2-O KO thymic Tregs (tTregs) expressed higher

levels of CD25, the high affinity IL-2 receptor, and Nur77, the orphan nuclear receptor (**Fig 2b**).

As Nur77 has been associated with the level of TCR engagement (22), increased expression of

Nur77 in H2-O KO Tregs suggests that they have been strongly signaled. Finally, maturation

state analyses uncovered that H2-O KO tTregs were enriched in the M1 stage (**Fig 2c**).

Peripheral Tregs are known to recirculate back to the thymus (23, 24). We, therefore

assessed the percentages of recirculating Tregs in H2-O Wt and H2-O KO thymi. **Figure 2d**

shows that similar levels of recirculating (CCR6+ CD73+) Tregs were present in both H2-O WT

and H2-O KO thymi. The results shown in Fig 2D are in agreement with the notion that

increased Mature Tregs are of de novo origin rather than recirculating.

**Loss of H2-O correlates with increased peripheral CD4 T cell activation**

Considering the observation that lack of H2-O did not appear to alter clonal deletion

frequencies but did affect the level of thymic CD4 T cell activation, we next evaluated whether

peripheral loss of H2-O also increased CD4 T cells activation.  Unimmunized H2-O KO spleens

had an increased frequency of CD4 T cells co-expressing the key activation markers CD44+ and

CD69+ (**Fig 3a**) and the tissue homing marker CCR7 (**Fig 3b**). We further assessed the levels of

"non-activated" (CCR7+ CD62L+) versus "activated" (CCR7- CD62L-) CD4 T cells (25), and found

lower frequencies of non-activated CD4 T cells in H2-O KO mice (**Fig 3c, left**). Importantly, this

correlated with an increase in percentage of activated CD4 T cells (**Fig 3c, right**). Collectively,

these phenotypic analyses support the idea that loss of H2-O leads to increased basal levels of

activated CD4 T cells in unimmunized H2-O KO mice.

As discussed above, H2-O KO thymi promoted Tregs selection. Consistent with these

observations and our previously published data (17, 26), H2-O KO spleens had an increased

frequency of CD25+ Foxp3+ Tregs (**Fig 3d**). Furthermore, H2-O KO Tregs showed decreased

levels of CD62L (**Fig 3e**) and increased levels of Nur77 (**Fig 3f)** indicating these cells are likely

more activated and circulating through the periphery.

**Single cell RNA-Sequencing of H2-O KO splenic CD4 T cells confirms increased activation**

Based upon the strong FACS data above exhibiting increased numbers of Tregs, and

more activated CD4 T cells, we attempted single-cell RNA-sequencing (scRNA-seq) to gain a

more holistic unbiased characterization. CD3+ CD4+ NK1.1- CD19- cells were sorted from

spleens of 3 unimmunized H2-O WT and 3 H2-O KO mice and subjected to 10x Genomics

scRNA-seq analyses. In total, 11 distinct CD4 T cell clusters were identified (**Fig 4a & sFig4**).

Separation of the clusters based upon H2-O WT or H2-O KO genotypes identified a dramatic

increase in cluster 0, cluster 2 and cluster 3 in the H2-O KO samples. Conversely, clusters 1 and

4 were significantly increased in H2-O WT samples (**Fig 4b**).

Comparing the genes from Clusters 0, 1 and 5 to the published CD4 T cell datasets using

the "My Geneset" function on the Immunological Genome Project (www.imgen.org) suggested

that upregulated genes (Log$_2$Avg Fold-change (FC) $\geq$ 0.5) were present in both "naïve" and

"activated" CD4 T cell datasets. Based upon the high expression of CCR7 however, these

clusters were labeled as "non-activated". Clusters 3, 6, 7, and 11 aligned with mainly an

"activated" CD4 T phenotype. Cluster 3 was found to have increased expression of the

activation marker CD44, while Cluster 11 expressed high Ki67. Clusters 2 and 4 contained the

known Treg genes Foxp3 and Il2ra (CD25) (**Fig 4a & Sup Table 1**). Clusters 8, 9, and 10 were

small populations of Macrophages and NKT cell (**Sup Table 1**). Condensing the cluster analysis

further supported our initial FACS data that unimmunized H2-O-KO mice have a decreased

frequency of "Non-activated" CD4 T cells (68.90% avg H2-O KO vs 74.17% avg H2-O WT with a

coinciding increase in "Activated" (14.14% avg H2-O KO vs 8.53% avg H2-O WT) CD4 T cells (**Fig**

**4b**).

To test whether the higher activated state in H2-O KO T cells were due to the H2-O KO

CD4 T cells themselves, or possibly induced by the *in vivo* environment, we performed an

adoptive transfer experiment of dye labeled naïve (CD4+ CD44- CD25-) Thy1.1+ CD4 T cells from

H2-O WT into either unimmunized Thy1.2+ H2-O WT, or Thy1.2+ H2-O KO hosts. As shown in

**Fig 4d**, H2-O KO hosts induced significantly more *in vivo* proliferation of the Thy1.1+ WT cells

than the H2-O WT hosts. These data additionally support the idea that loss of H2-O creates a

more activating CD4 T cell environment by presenting a wider range of self-epitopes (17).

**H2-O KO Tregs have an activated phenotype**

Analyses of the two Treg clusters revealed that the frequency of Clusters 2 and 4 were

roughly equal in H2-O WT samples, whereas H2-O KO samples had an overrepresentation of

Cluster 2 (**Fig 5a, left**).  Both cluster 2 and 4 expressed the classic Treg genes Foxp3, IL2ra

[CD25], CTLA4, and Pdcd1 [PD-1] (**Fig 5a, right**; **Sup Table 1**). Also identified was the

transcription factor Ikzf2 [Helios], a marker of stable Treg lineage commitment in inflammatory

conditions (27) and debated marker of thymic Tregs (28, 29, 30, 31). Supporting our scRNA-Seq

analysis, Helios protein expression was found in both H2-O WT and H2-O KO CD4 Tregs (**Fig 5b**).

Comparison of the cluster 2 genetic signature with a published Treg data set indicated that

these cells are likely effector-like Tregs. Furthermore, breaking down Cluster 2 by genotype

showed that H2-O KO Tregs had a larger fold change in expression of the core effector genes

signature (32) (**Fig 5c**). We hypothesize that this activated Treg state is likely driven by the

increased basal CD4 T cell activation. Expansion of this Treg population could certainly be a

mechanism controlling spontaneous autoimmunity in H2-O KO mice.

In summary, both scRNA-seq and FACs analyses showed that H2-O KO mice have an

increased frequency of both conventional and regulatory CD4 T cells in the spleens of

unimmunized mice. Loss of thymic H2-O expression correlated with an increased tTreg

population that was not from peripheral recirculation and had received increased TCR

stimulation, which suggests an increased autoreactivity. Furthermore, increased activation of

conventional splenic CD4 T cells is likely a driving factor for the increased effector-like Treg

status that was identified by scRNA-seq analyses of H2-O-KO CD4 cells.

193                              **Discussion**

In this study, we have refined our understanding of how loss of H2-O alters CD4 T cell

activity *in vivo*. Thymic analysis of medulla localized CD4 T cells pointed to a novel role for H2-O

on CD4 T cells undergoing self-auditing. Importantly, lack of H2-O expression led to an

increased frequency of both thymic and peripheral Tregs.

Tregs play a fundamental role in maintenance of homeostasis, hence a better

understanding of the mechanism of their development is highly desirable and the subject of

numerous studies (15, 19). Our studies here are the first attempt in demonstrating that H2-O

plays a role in Treg development.  While the exact mechanism by which thymic Treg cells are

selected remains somewhat uncertain, recent studies support the idea that intermittent TCR

signaling along with cytokine signaling drive Treg development (16). These findings and others

(33, 34, 35, 36, 37) support a more avidity based model of Treg selection, in which alterations to

the density of self-ligands present in the medulla will have differential effects on CD4 T cell

selection. Intermittent TCR signaling as a driving force in Treg selection is very relevant to our

understanding of how HLA-DO contributes to epitope selection during antigen processing. We

have proposed that HLA-DO in complex with HLA-DM leads to better refinement of the

epitopes from denatured antigens, promoting selection of the best fitting epitopes in the

groove of MHC II molecules (11, 38). While this idea might appear in conflict with the multiple

earlier interpretations of DO function (39, 40, 41), recent studies using human HLA-DO variants

showed that certain variants enhanced DM activity (42).

Understanding of how DO works has been tumultuous over the past decades (5, 43, 44,

45, 46, 47, 48, 49). DO has been proposed to be an inhibitor of DM, or a helper of DM. Most

reports acknowledge that understanding of DO requires further research. Our model that is

based on studying kinetics of interactions of DO with DM and MHC class II using a variety of

peptides of different binding characteristics is the most direct investigation of the biochemical

mechanism of DO function. The most important evidence for our model come from data

showing that DO or DO/DM binds to DR1 in a peptide receptive conformation: DO does not

bind to the DR1 in complex with tightly bound peptides.  Based on this model, when DO is

present, higher affinity peptides are more likely to be presented. Conversely, in the absence of

DO a larger percent of lower affinity epitopes are selected. Indeed, our in vivo peptide elution

studies supports this biochemical mechanism as peptides eluted from H2-O KO mice expressing

murine I-A[b] (17) were of a lower general affinity. Accordingly, presentation of a larger portion

of lower affinity peptides in the thymic medulla of H2-O KO mice is possible. Intermittent TCR

signaling is typically generated by either pMHCII that are less stable (50, 51, 52, 53), or

TCR/pMHC of lower affinity (54). Our findings here support the former. We associate increased

Treg development as a consequence of the presentation of lower affinity peptides to self-

auditing CD4 T cells.

Due to the continuous egress of mature CD4 T cells from the thymus, we also analyzed

splenic CD4 T cells from unimmunized H2-O WT and H2-O KO mice. H2-O KO splenic CD4 T cells

in unimmunized mice revealed an increased frequency of CD44hiCD69+ antigen experienced

CD4 T cells, which suggests an increased level of antigen-specific TCR signaling in H2-O KO mice.

As previously implied (55), a simple explanation for this activated state is incomplete thymic

deletion in H2-O KO mice. While we were able to show that H2-O KO mice failed to delete

specific CD4 clonal populations (17), detection of differences at the global levels did not show

significant changes between the two genotypes.  Nonetheless, we suggest that presentations of

different arrays of self-antigens as well as their lower densities on thymic medulla leads to a

less than optimal thymic deletion of self-reactive CD4 T cells and their routing to the periphery.

Similar to activated CD4 T cells in the periphery, H2-O KO Treg cells also had a more effector-

like phenotype, indicating enhanced Treg activation in unimmunized mice (32, 56).

In conclusion, our studies add a new dimension to our understanding of the role of H2-O

in both CD4 T cell selection and activation. For the first time, we report on thymic negative

selection in H2-O KO mice and demonstrate that loss of H2-O enhances thymic selection of

regulatory T cells. Once in the periphery, an increased proportion of H2-O KO Tregs appear to

be activated in a TCR dependent manner. These effector-like Tregs will likely help control

increased basal CD4 T cell activation. However, the exact mechanism by which increased Treg

cells are selected in the H2-O KO thymus remains to be determined. While we propose that

alterations in medulla pMHCII-TCR avidity interactions could lead to enhanced Treg selection,

increased presentation of self-antigens in a more tissue restricted antigenic (TRA) manner could

also be possible (15).

252
253

254 **Methods**

## Mice

Male and female C57BL/6J (H2-O WT, stock no: 000664), Female B6.PL-Thy1a/CyJ (stock
no: 000406) were purchased from Jackson Laboratories and bred in house. Generation of the
H2-O knock-out mice has been previously described (57) and mice bred in house. Unless
otherwise stated analyzed mice were 6-8 weeks. All mouse procedures were approved by the
Johns Hopkins University Animal Care and Use Committee and were following relevant ethical
regulations.

## Antibodies/reagents

**Flow Cytometry**: anti-CD3e (17A2), anti-CD4 (RM4-5), anti-CD5 (53-7.3), anti-CD8α (53-6.7),
CD11c (N418), anti-CD19 (ID3), anti-CD25 (PC61), anti-CD44 (IM7), anti-CD45R/B220 (RA3-6B2),
anti-CD62L (MEL-14), anti-CD69 (H1.2F3), anti-CD197/CCR7 (4B12), anti-NK1.1 (PK136), anti-
TCRβ (H57-597), anti-TCRγδ (GL3), anti-Cleaved Caspase 3 (D3E9) Cell signaling (Danvers, MA);
Foxp3 (150D), anti-Helios (22F6), anti-Nur77 (12.14), Fixable viability dye eFluor 780
(eBioscience).

**FACs Sorting**: anti-CD3e, anti-CD4, anti-CD19, anti-NK1.1, Propidium iodide. Briefly, 30,000 live
CD4 T cells [Gating: CD3+, CD4, CD19-, NK1.1-, PI-] were FACs sorted from the spleens of 3
unimmunized 10 week-old H2-O WT and 3 unimmunized 10 week-old unimmunized H2-O KO
female mice.

## Cell staining

For cleaved caspase 3 staining (18) homogenized mice thymocyte cells were stained
with anti-CCR7/CD197 at a final dilution of 1:50 for 30 min at 37°C prior to additional surface
stains. Following surface staining, cells were fixed with Cytofix/Cytoperm (BD Biosciences) for
20 min at 4°C. Cells were then washed with Perm/Wash buffer (BD Biosciences) twice. Cells
were stained with anti–cleaved caspase 3 at a 1:50 dilution at 23°C for 30 min.
For transcription factor staining, cells were incubated with surface antibody at 4°C for 20
min, permeabilized at 4°C for 30 min using a Foxp3/Transcription factor buffer set (Invitrogen,
ThermoFisher Scientific), and then stained with anti–Foxp3 and/or anti-Helios at 23°C for 30
min.

## Adoptive Cell Transfer

288 Naïve CD4 T cells were isolated from the pooled spleens and LNs of 4 week old Thy1.1
289 expressing C57BL/6J mice using the EasySep Mouse Naive CD4 T cell Isolation Kit (StemCell
290 Technologies). Isolated cells were stained with eFluor 450 viability dye (eBiosciences) according
291 to manufactures directions. $3\times10^6$ dye labeled Thy1.1 cells were IV injected into 10 week old
292 H2-O WT or H2-O KO hosts. Transferred cells were recovered 7 days post-transfer.

## scRNA-Sequencing

295 **Library & sequencing**
296 The samples were prepared using the 10x Genomics Chromium Next GEM Single Cell 5' Library

297 and Gel Bead Kit v1.1, Chromium Next GEM Chip and Dual Index Kit TN Set A. They were run on
298 the Illumina NovaSeq6000 with a run configuration of 28bp x 10bp x 10bp x 91bp.
299
**Analysis**
Analyses of T-cell scRNA-seq were performed with the package Seurat (58), as follows. Data was
filtered to remove cells with low gene count (<200), large number of UMIs (>12,000) and high
(>5%) fraction of mitochondrial reads. Expression levels of genes were log-normalized, and the
most variable 2000 genes were selected for linear dimensionality reduction with Principal
Component Analysis (PCA). The first 15 principal components were then used to performed
unsupervised clustering using the Seurat SNN clustering package, with a resolution of 0.2. To
identify cell types, potential markers for each cluster were calculated as the set of genes
significantly differentially expressed in each cluster compared to all others, using the function
FindAllMarkers, and by searching existing literature and marker databases. Lastly, differentially
expressed genes for each cell type between conditions were determined using the function
FindMarkers with the default function (bimod).
312
313 Defining clusters – Genes with an average fold-change (avgFC) >0.5 and an adjusted p-value
314 <0.05 were run against CD4 T cell data sets available on the Immunological Genome Project
315 (https://www.immgen.org/) using the "My Geneset" data browser function.
316

317 **Statistical testing**
318 GraphPad Prism was used for all statistical analyses. A standard Student T-test was used for
319 estimation of statistical significance. Data is shown as mean ± SEM. *p<0.05, **p<0.01,
320 ***p<0.001, ****p<0.0001.
321

**Acknowledgments**
Authors thank Drs Lars Karlsson and Peter Jensen for the gift of H2-O KO mice. We also thank
Dr. Liliana D. Florea, and Corina Antonescu from the Computational Biology Computing Core at
Johns Hopkins School of Medicine for help with scRNA-Seq analysis. FACs analysis was
performed in the BD Immunology and Flow Cytometry Laboratory at the Johns Hopkins School
of Public Health.  Supported by grants  from NIAID, R01AI063764, R21AI101987, and
R01AI120634, to SS-N.

329
330
331

**Figure 1**: Loss of thymic H2-O increases the activation state of auditing CD4 T cells

**A. Left**: representative contour plots showing total CD69 expression in auditing (Caspase-3

negative) signaled (TCR-B+CD5+) CCR7+CD4+ T cells from 6-week-old H2-O WT (Top) and H2-O

KO (Bottom) thymi.

**Right**: Combined CD69 expression data from 5 repeat experiments. N= 18 mice per genotype

**B. Right**: representative contour plots showing total CD69 expression in Clonally deleted

(Caspase-3 positive) signaled (TCR-B+CD5+) CCR7+CD4+ T cells from 6-week-old H2-O WT (Top)

and H2-O KO (Bottom) thymi.

**Left**: Combined CD69 expression data from 5 repeat experiments. N= 18 mice per genotype

**C. Top**: representative contour plots showing the subdivision of auditing (Caspase-3 negative)

signaled (TCR-B+CD5+) CCR7+CD4+ T cells from 6-week-old H2-O WT (Left) and H2-O KO (Right)

thymi into three maturation stages: Semi-Mature (SM), Mature 1 (M1), and Mature 2 (M2).

**Bottom**: Cumulative maturation state data from 5 repeat experiments, N = 18 mice per

genotype.

Expression has been normalized to the average H2-O WT levels within each experiment to

allow for comparison across experiments. Raw percentage data can be found in Supplemental

Figure 3.

**D**. Frequency of medulla specific (CCR7+) CD4 T cells selected for clonal deleted (Caspase-3+)

ns = not significant

* = <0.05

** = <0.001

***= <0.0001

**** = <0.00001

Statistics: unpaired student T-test

**Figure 2: H2-O KO thymi have increased selection of regulatory T cells**

**A. Left**: representative contour plots showing the frequency of Tregs (CD25+ Foxp3+) cells in

the CD4 single-positive thymus population.

**Right**: cumulative percentage of Foxp3+ CD25+ cells within the CD4 single-positive thymus

population in H2-O WT (white) or H2-O KO (red) cells. Data from 3 replicate experiments, N= 16

mice per genotype.

**B**. Geometric mean fluorescence intensity (gMFI) of CD25 (left), and Nur77 (right) expressed by

Foxp3+ CD4+ T cells in the thymus of H2-O WT (white) or H2-O KO (red) mice.

**C**. Subdivision of Treg cells into three maturation stages: Semi-Mature (Left), Mature 1 (Middle),

and Mature 2 (Right). Data from 2 replicate experiments.

**D. Left**: representative contour plots showing the frequency of Naive (CCR6- CD73-), Mature

(CCR6- CD73+), and Recirculating (CCR6+ CD73+) Foxp3+ CD25+ Tregs in 6-week-old H2-O WT

and H2-O KO thymi.

**Right**: Summary plots showing the frequency of Naive (CCR6- CD73-), Mature (CCR6- CD73+),
and Recirculating (CCR6+ CD73+) Foxp3+ CD25+ Tregs from 2 independent repeat experiments,
N= 6 mice per group.
377
**Figure 3: H2-O KO mice have an increased activated peripheral CD4 T cell population**
**A.** Basal levels of CD44 and CD69 expressed by H2-O WT (white) and H2-O KO (red) splenic CD4
T cells. Increased CD69 expression, a marker of recent activation showed increased levels on
H2-O KO CD4 T cells
**B.** Percentage of CD4+ T cells expressing the lymphoid tissue homing receptor CCR7
**C.** CCR7 and CD62L expression levels in unimmunized splenic CD4 T cells
**D.** Frequency of Foxp3+CD25+ cells in splenic CD4+ T cell population of unimmunized mice
**E.** H2-O KO peripheral Tregs express decreased levels of naïve (CD44+ CD62L+) expressing cells
**F.** Normalized Nur77 gMFI levels in Foxp3+CD25+ Treg cells in H2-O WT (white) and H2-O KO
(red) cells. To account for experimental variation the average Nur77 gMFI level in H2-O WT
samples was calculated. gMFI levels in both H2-O WT and H2-O KO samples were then divided
by the calculated H2-O WT average. An increased Nur77 ratio indicates increased Nur77 gMFI
levels. Summary of 3 repeat experiments.
391
392    * = <0.05
393    ** = <0.001
394    *** = <0.0001
395    **** = <0.00001
396
**Figure 4**: **Loss of H2-O function causes increased basal CD4 cell activation**
**A.** scRNA-seq clustering of CD4 T cells after Seurat analysis. Data represents the average of of 3
biological replicates per genotype.
**B.** Breakdown of clusters in H2-O WT (Left) or H2-O KO (Right) samples. Clusters are grouped
based upon, (1) known CD4 T cell subset markers and (2) gene comparison to published CD4 T
cell data sets available on the Immunological Genome Project (www.immgen.org). Identified
CD4 Cell phenotypes were: Non-activated, Activated, and Regulatory T cells. "Other" refers to a
minor macrophage and NKT cell contamination from the sorting process.
**C.** Distribution of the for the Non-activated and Activated phenotypes across the H2-O WT and
H2-O KO biological replicates (N = 3 mice per genotype).
**D.** In vivo proliferation of adoptively transferred naïve Thy1.1+ CD4 T cells (Thy1.1+ CD3+ CD4+
CD44- CD25-) after 7 days in either Thy1.2 H2-O WT (white) or Thy1.2 H2-O KO (red) hosts.
Pooled data from 2 independent experiments (N= 6 H2-O WT, 5 H2-O KO)
410
**Figure 5**: **The H2-O KO Treg population has a more effector like phenotype**
**A.** (Left) distribution of the two Treg populations identified by scRNA-seq clustering in either
H2-O WT (left) or H2-O KO (right) samples. (Right) Expression of key Treg phenotypic markers:
Foxp3 (Top) and CD25 [Il2ra] (Bottom)
**B.** Subdivision of the splenic CD4+ T cell population by Foxp3 and Helios expression
**C.** Comparison of cluster 2 upregulated genes (Log$_2$Avg FC >0.5) in H2-O WT and H2-KO samples
to a published (Miragaia *et al*.) splenic effector Treg genetic profile

**Supplemental Figure 1: Gating strategy used for detection of Auditing vs Clonally Deleted Medulla CD4 T cells**

Red arrows indicate how Auditing vs Clonal Deletion was identified in 6-week-old H2-O WT and H2-O KO thymi.

Blue arrows indicate additional gating corresponding to Figure 1a.

Black Arrows indicate additional gating corresponding to Figure 1b.

**Supplemental Figure 2: The frequency of auditing Mature 1 CD4 T cells was increased in H2-O KO thymi**

**A**. Percentage of auditing (Caspase-3 negative) CD4 T cells in the Semi-mature (CD69+ MHC-I neg), Mature 1 (CD69+ MHC-1+), and Mature 2 (CD69- MHC-I+) in H2-O WT (white) and H2-O KO (red) mice N= 18 mice per group

**B**. Percentage of clonally deleted (Caspase-3+) CD4 T cells in the Semi-mature (CD69+ MHC-I neg), Mature 1 (CD69+ MHC-1+), and Mature 2 (CD69- MHC-I+) in H2-O WT (white) and H2-O KO (red) mice. N= 18 mice per group

Statistical Testing: unpaired student T-test

**Supplemental Figure 3: Positive Selection is not affected by loss of H2-O**

A. Representative plots showing CD4, CD8 and Double Positive (DP) percentages in H2-O WT (Top) and H2-O KO (Bottom)

B. Summary plots of the single-positive CD4 (Top) and CD8 (Bottom) percentages from 5 repeat experiments.

C. (Left) representative flow plots showing the "Signaled" vs "Non-signaled" thymocytes in H2-O WT (Top) or H2-O KO (Bottom).

   (Right) Summary plots of >5 repeat experiments.

D. Frequency of signaled CCR7+ medulla CD4 T cells in H2-O WT (white) and H2-O KO (red) mice

**Supplemental Figure 4**:

Top: breakdown of H2-O KO (right) and H2-O WT (Left) Seurat clustering

Bottom: Seurat clustering for each individual biological replicate

**Bibliography**

1.      Murphy K, Weaver C. Janeway's Immunobiology. New York & London: Garland Science;
2016 2016.

2.      Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad
after neonatal thymectomy in mice. Science. 1969;166(3906):753-5.

3.      Karlsson L, Surh CD, Sprent J, Peterson PA. A novel class II MHC molecule with unusual
tissue distribution. Nature. 1991;351(6326):485-8.

4.      Hornell TM, Burster T, Jahnsen FL, Pashine A, Ochoa MT, Harding JJ, et al. Human
dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J Immunol.
2006;176(6):3536-47.

5.      Chen X, Reed-Loisel LM, Karlsson L, Jensen PE. H2-O expression in primary dendritic
cells. Journal of immunology. 2006;176(6):3548-56.

6.      Narayan K, Su KW, Chou CL, Khoruzhenko S, Sadegh-Nasseri S. HLA-DM mediates
peptide exchange by interacting transiently and repeatedly with HLA-DR1. Mol Immunol.
2009;46(15):3157-62.

7.      Chou CL, Mirshahidi S, Su KW, Kim A, Narayan K, Khoruzhenko S, et al. Short peptide
sequences mimic HLA-DM functions. Mol Immunol. 2008;45(7):1935-43.

8.      Natarajan SK, Assadi M, Sadegh-Nasseri S. Stable peptide binding to MHC class II
molecule is rapid and is determined by a receptive conformation shaped by prior association
with low affinity peptides. J Immunol. 1999;162(7):4030-6.

9.      Sadegh-Nasseri S. A step-by-step overview of the dynamic process of epitope selection
by major histocompatibility complex class II for presentation to helper T cells. F1000Res.
2016;5.

10.     Alfonso C, Williams GS, Han JO, Westberg JA, Winqvist O, Karlsson L. Analysis of H2-O
influence on antigen presentation by B cells. J Immunol. 2003;171(5):2331-7.

11.     Poluektov YO, Kim A, Hartman IZ, Sadegh-Nasseri S. HLA-DO as the optimizer of epitope
selection for MHC class II antigen presentation. PloS One. 2013;8(8):e71228.

12.     Savage PA, Klawon DEJ, Miller CH. Regulatory T Cell Development. Annu Rev Immunol.
2020;38:421-53.

13.     Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev
Immunol. 2012;12(3):157-67.

14.     Tai X, Erman B, Alag A, Mu J, Kimura M, Katz G, et al. Foxp3 transcription factor is
proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine
survival signals. Immunity. 2013;38(6):1116-28.

15.     Klein L, Robey EA, Hsieh CS. Central CD4(+) T cell tolerance: deletion versus regulatory T
cell differentiation. Nat Rev Immunol. 2019;19(1):7-18.

16.    Tai X, Indart A, Rojano M, Guo J, Apenes N, Kadakia T, et al. How autoreactive
thymocytes differentiate into regulatory versus effector CD4(+) T cells after avoiding clonal
deletion. Nat Immunol. 2023;24(4):637-51.

17.    Welsh RA, Song N, Foss CA, Boronina T, Cole RN, Sadegh-Nasseri S. Lack of the MHC
class II chaperone H2-O causes susceptibility to autoimmune diseases. PLoS Biol.
2020;18(2):e3000590.

18.    Breed ER, Watanabe M, Hogquist KA. Measuring Thymic Clonal Deletion at the
Population Level. J Immunol. 2019;202(11):3226-33.

19.    Li MO, Rudensky AY. T cell receptor signalling in the control of regulatory T cell
differentiation and function. Nat Rev Immunol. 2016;16(4):220-33.

20.    Nanaware PP, Jurewicz MM, Leszyk J, Shaffer SA, Stern LJ. HLA-DO modulates the
diversity of the MHC-II self-peptidome. Mol Cell Proteomics. 2018.

21.    Yi W, Seth NP, Martillotti T, Wucherpfennig KW, Sant'Angelo DB, Denzin LK. Targeted
regulation of self-peptide presentation prevents type I diabetes in mice without disrupting
general immunocompetence. J Clin Invest. 2010;120(4):1324-36.

22.    Moran AE, Holzapfel KL, Xing Y, Cunningham NR, Maltzman JS, Punt J, et al. T cell
receptor signal strength in Treg and iNKT cell development demonstrated by a novel
fluorescent reporter mouse. J Exp Med. 2011;208(6):1279-89.

23.    Thiault N, Darrigues J, Adoue V, Gros M, Binet B, Perals C, et al. Peripheral regulatory T
lymphocytes recirculating to the thymus suppress the development of their precursors. Nat
Immunol. 2015;16(6):628-34.

24.    Santamaria JC, Borelli A, Irla M. Regulatory T Cell Heterogeneity in the Thymus: Impact
on Their Functional Activities. Front Immunol. 2021;12:643153.

25.    Golubovskaya V, Wu L. Different Subsets of T Cells, Memory, Effector Functions, and
CAR-T Immunotherapy. Cancers (Basel). 2016;8(3).

26.    Welsh R, Sadegh-nasseri S. The love and hate relationship of HLA-DM/DO in the
selection of immunodominant epitopes. Curr Opin Immunol. 2020;64:117–23.

27.    Lam AJ, Uday P, Gillies JK, Levings MK. Helios is a marker, not a driver, of human Treg
stability. Eur J Immunol. 2022;52(1):75-84.

28.    Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression of
Helios, an Ikaros transcription factor family member, differentiates thymic-derived from
peripherally induced Foxp3+ T regulatory cells. J Immunol. 2010;184(7):3433-41.

29.    Thornton AM, Lu J, Korty PE, Kim YC, Martens C, Sun PD, et al. Helios(+) and Helios(-)
Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR
repertoires. Eur J Immunol. 2019;49(3):398-412.

30.    Serre K, Benezech C, Desanti G, Bobat S, Toellner KM, Bird R, et al. Helios is associated
with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of
Foxp3 expression. PLoS One. 2011;6(6):e20731.

31.    Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression is a marker of
T cell activation and proliferation. PLoS One. 2011;6(8):e24226.

32.    Miragaia RJ, Gomes T, Chomka A, Jardine L, Riedel A, Hegazy AN, et al. Single-Cell
Transcriptomics of Regulatory T Cells Reveals Trajectories of Tissue Adaptation. Immunity.
2019;50(2):493-504 e7.

33.    Simons DM, Picca CC, Oh S, Perng OA, Aitken M, Erikson J, et al. How specificity for self-
peptides shapes the development and function of regulatory T cells. J Leukoc Biol.
2010;88(6):1099-107.

34.    Relland LM, Mishra MK, Haribhai D, Edwards B, Ziegelbauer J, Williams CB. Affinity-
based selection of regulatory T cells occurs independent of agonist-mediated induction of
Foxp3 expression. J Immunol. 2009;182(3):1341-50.

35.    Picca CC, Oh S, Panarey L, Aitken M, Basehoar A, Caton AJ. Thymocyte deletion can bias
Treg formation toward low-abundance self-peptide. Eur J Immunol. 2009;39(12):3301-6.

36.    Feuerer M, Jiang W, Holler PD, Satpathy A, Campbell C, Bogue M, et al. Enhanced thymic
selection of FoxP3+ regulatory T cells in the NOD mouse model of autoimmune diabetes. Proc
Natl Acad Sci U S A. 2007;104(46):18181-6.

37.    Atibalentja DF, Murphy KM, Unanue ER. Functional Redundancy between Thymic
CD8{alpha}+ and Sirp{alpha}+ Conventional Dendritic Cells in Presentation of Blood-Derived
Lysozyme by MHC Class II Proteins. J Immunol. 2011;186(3):1421-31.

38.    Poluektov YO, Kim A, Sadegh-Nasseri S. HLA-DO and Its Role in MHC Class II Antigen
Presentation. Frontiers in immunology. 2013;4:260.

39.    Alfonso C, Liljedahl M, Winqvist O, Surh CD, Peterson PA, Fung-Leung WP, et al. The role
of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing
and presentation. Immunol Rev. 1999;172:255-66.

40.    Denzin LK. Inhibition of HLA-DM Mediated MHC Class II Peptide Loading by HLA-DO
Promotes Self Tolerance. Front Immunol. 2013;4:465.

41.    Guce AI, Mortimer SE, Yoon T, Painter CA, Jiang W, Mellins ED, et al. HLA-DO acts as a
substrate mimic to inhibit HLA-DM by a competitive mechanism. Nature structural & molecular
biology. 2013;20(1):90-8.

42.    Denzin LK, Khan AA, Virdis F, Wilks J, Kane M, Beilinson HA, et al. Neutralizing Antibody
Responses to Viral Infections Are Linked to the Non-classical MHC Class II Gene H2-Ob.
Immunity. 2017;47(2):310-22 e7.

43.    Kropshofer H, Hammerling GJ, Vogt AB. The impact of the non-classical MHC proteins
HLA-DM and HLA-DO on loading of MHC class II molecules. Immunol Rev. 1999;172:267-78.

44.    Kropshofer H, Vogt AB, Thery C, Armandola EA, Li BC, Moldenhauer G, et al. A role for
HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. Embo J.
1998;17(11):2971-81.

45. van Ham M, van Lith M, Griekspoor A, Neefjes J. What to do with HLA-DO?
Immunogenetics. 2000;51(10):765-70.

46. Jiang W, Strohman MJ, Somasundaram S, Ayyangar S, Hou T, Wang N, et al. pH-
susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity. Sci Rep.
2015;5:17333.

47. Fallas JL, Tobin HM, Lou O, Guo D, Sant'Angelo DB, Denzin LK. Ectopic expression of HLA-
DO in mouse dendritic cells diminishes MHC class II antigen presentation. J Immunol.
2004;173(3):1549-60.

48. Draghi NA, Denzin LK. H2-O, a MHC class II-like protein, sets a threshold for B-cell entry
into germinal centers. Proc Natl Acad Sci U S A. 2010;107(38):16607-12.

49. Welsh R, Song N, Sadegh-Nasseri S. What to do with HLA-DO/H-2O two decades later?
Immunogenetics. 2019;71(3):189-96.

50. Mirshahidi S, Ferris LC, Sadegh-Nasseri S. The magnitude of TCR engagement is a critical
predictor of T cell anergy or activation. J Immunol. 2004;172(9):5346-55.

51. Sadegh-Nasseri S, Dalai SK, Korb Ferris LC, Mirshahidi S. Suboptimal engagement of the
T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy. Immunology.
2010;129(1):1-7.

52. Baumgartner CK, Ferrante A, Nagaoka M, Gorski J, Malherbe LP. Peptide-MHC class II
complex stability governs CD4 T cell clonal selection. J Immunol. 2010;184(2):573-81.

53. Smyth LA, Williams O, Huby RDJ, Norton T, Acuto O, Ley SC, et al. Altered peptide
ligands induce quantitatively but not qualitatively different intracellular signals in primary
thymocytes. PNAS. 1998;95(14):8193-8.

54. Lucas B, Stefanova I, Yasutomo K, Dautigny N, Germain RN. Divergent changes in the
sensitivity of maturing T cells to structurally related ligands underlies formation of a useful T
cell repertoire. Immunity. 1999;10(3):367-76.

55. Gu Y, Jensen PE, Chen X. Immunodeficiency and autoimmunity in H2-O-deficient mice.
Journal of immunology. 2013;190(1):126-37.

56. Shevyrev D, Tereshchenko V. Treg Heterogeneity, Function, and Homeostasis. Front
Immunol. 2019;10:3100.

57. Liljedahl M, Winqvist O, Surh CD, Wong P, Ngo K, Teyton L, et al. Altered antigen
presentation in mice lacking H2-O. Immunity. 1998;8(2):233-43.

58. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, et al.
Comprehensive Integration of Single-Cell Data. Cell. 2019;177(7):1888-902 e21.

**A.**

**B.**

H2-O WT

| | H2-O WT | | H2-O KO |
|---|---|---|---|
| 37.96% Cluster 0 | | 58.84% Cluster 0 | Non-activated |
| 31.35% Cluster 1 | | 7.34% Cluster 1 | |
| 4.87% Cluster 5 | | 2.72% Cluster 5 | |
| 4.97% Cluster 3 | | 8.65% Cluster 3 | Activated |
| 2.07% Cluster 6 | | 3.21% Cluster 6 | |
| 1.34% Cluster 7 | | 1.94% Cluster 7 | |
| 0.14% Cluster 11 | | 0.34% Cluster 11 | |
| 7.58% Cluster 2 | | 12.17% Cluster 2 | Treg |
| 6.81% Cluster 4 | | 2.36% Cluster 4 | |
| 1.58% Cluster 8 | | 1.53% Cluster 8 | Other |
| 0.72% Cluster 9 | | 0.79% Cluster 9 | |
| 0.60% Cluster 10 | | 0.11% Cluster 10 | |

H2-O KO

**C.**

**D.** Thy1.1 Transferred Cells

○ H2-O WT
● H2-O KO